StreetInsider.com News Articles

Form 6-K Satellos Bioscience Inc. For: Feb 24

Tue, 24 Feb 2026 07:15:00 +0000

si-local-file:///var/storage/secattach/20260224/26046639.html

Form 6-K Satellos Bioscience Inc. For: Feb 24

Tue, 24 Feb 2026 07:15:00 +0000

si-local-file:///var/storage/secattach/20260224/26046639.html

Form 6-K Satellos Bioscience Inc. For: Feb 24

Tue, 24 Feb 2026 07:15:00 +0000

si-local-file:///var/storage/secattach/20260224/26046639.html

Form 6-K Satellos Bioscience Inc. For: Feb 19

Thu, 19 Feb 2026 11:05:00 +0000

si-local-file:///var/storage/secattach/20260219/26027888.html

Form 6-K Satellos Bioscience Inc. For: Feb 19

Thu, 19 Feb 2026 11:05:00 +0000

si-local-file:///var/storage/secattach/20260219/26027888.html

Form 6-K Satellos Bioscience Inc. For: Feb 19

Thu, 19 Feb 2026 11:05:00 +0000

si-local-file:///var/storage/secattach/20260219/26027888.html

Form 6-K Satellos Bioscience Inc. For: Feb 18

Wed, 18 Feb 2026 14:03:00 +0000

si-local-file:///var/storage/secattach/20260218/26020753.html

Form 6-K Satellos Bioscience Inc. For: Feb 18

Wed, 18 Feb 2026 14:03:00 +0000

si-local-file:///var/storage/secattach/20260218/26020753.html

Form 6-K Satellos Bioscience Inc. For: Feb 18

Wed, 18 Feb 2026 14:03:00 +0000

si-local-file:///var/storage/secattach/20260218/26020753.html

Form 6-K Satellos Bioscience Inc. For: Feb 17

Tue, 17 Feb 2026 15:23:00 +0000

si-local-file:///var/storage/secattach/20260217/26011634.html

Form 6-K Satellos Bioscience Inc. For: Feb 17

Tue, 17 Feb 2026 15:23:00 +0000

si-local-file:///var/storage/secattach/20260217/26011634.html

Form 6-K Satellos Bioscience Inc. For: Feb 17

Tue, 17 Feb 2026 15:23:00 +0000

si-local-file:///var/storage/secattach/20260217/26011634.html

Form 6-K Satellos Bioscience Inc. For: Feb 10

Thu, 12 Feb 2026 07:15:00 +0000

si-local-file:///var/storage/secattach/20260212/25987171.html

Form 6-K Satellos Bioscience Inc. For: Feb 10

Thu, 12 Feb 2026 07:15:00 +0000

si-local-file:///var/storage/secattach/20260212/25987171.html

Form 6-K Satellos Bioscience Inc. For: Feb 10

Thu, 12 Feb 2026 07:15:00 +0000

si-local-file:///var/storage/secattach/20260212/25987171.html

Satellos begins phase 2 trial of SAT-3247 for duchenne muscular dystrophy

Thu, 12 Feb 2026 07:00:16 +0000

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced that the first participant has been dosed in its BASECAMP phase 2 pediatric study evaluating SAT-3247 for Duchenne muscular dystrophy.

The three-month, randomized, double-blind, placebo-controlled study will evaluate 51 ambulatory children with DMD aged 7, 8 or 9 years. Primary endpoints include safety, tolerability and effect on muscle force. Secondary endpoints will assess the drug's impact on muscle quality, function and regeneration.

"Designed as a potential pivotal trial, BASECAMP marks a significant step for Satellos in evaluating the therapeutic potential of SAT-3247 in children living with Duchenne," said Frank Gleeson, co-founder and CEO. "Data

Satellos begins phase 2 trial of SAT-3247 for duchenne muscular dystrophy

Thu, 12 Feb 2026 07:00:16 +0000

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced that the first participant has been dosed in its BASECAMP phase 2 pediatric study evaluating SAT-3247 for Duchenne muscular dystrophy.

Satellos begins phase 2 trial of SAT-3247 for duchenne muscular dystrophy

Thu, 12 Feb 2026 07:00:16 +0000

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced that the first participant has been dosed in its BASECAMP phase 2 pediatric study evaluating SAT-3247 for Duchenne muscular dystrophy.

Satellos begins phase 2 trial of SAT-3247 for duchenne muscular dystrophy

Thu, 12 Feb 2026 07:00:16 +0000

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced that the first participant has been dosed in its BASECAMP phase 2 pediatric study evaluating SAT-3247 for Duchenne muscular dystrophy.

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

Thu, 12 Feb 2026 07:00:00 +0000

BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247’s safety and tolerability, and effect on muscle force, muscle quality and muscle regeneration

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy (“Duchenne” or “DMD”).